

Compendium of WHO guidelines and associated standards:

ensuring optimum delivery of the cascade of care for patients with tuberculosis

Second edition - June 2018

DENIONES

DRUG-RESISTANCE Z MONITORING & EVALUATION

XDR-TB M COMMUNITY ENGAGEMENT

TB/HIV Z COMORBID CONDITIONS

PATIENT CARE AND SUPPORT

COMMUNITY
DIGITAL HEALTH

INFECTION CONTROL





Compendium of WHO guidelines and associated standards:

ensuring optimum delivery of the cascade of care for patients with tuberculosis

Second edition - June 2018





Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis, second edition

ISBN 978-92-4-151410-1

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis, second edition. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Spain

Contents

	Foreword	iv
	Acknowledgements	v
	Abbreviations	vi
1.	Introduction	1
	1.1 The END TB Strategy	2
	1.2 Scope of the Compendium	3
	1.3 Ethical Considerations	4
	1.4 Community Engagement	4
	1.5 Public-Private Mix	5
2.	WHO policy development process	7
3.	Early detection of TB	9
4.	Diagnosing TB disease	12
5.	Diagnosing latent TB infection	18
6.	Treating TB	19
	6.1 Treating drug-susceptible TB	19
	6.2 Treating drug-resistant TB	20
	6.3 Treating latent TB infection	24
7.	HIV infection and other co-morbid conditions	26
8.	Managing TB in children	29
9.	Monitoring and evaluation	32
10.	Supportive approaches	35
	10.1 Digital health	35
	10.2 Infection control	35
	10.3 Patient care and support	37
	10.4 Palliative care	38

Foreword

Tuberculosis (TB) is the single leading infectious cause of mortality. Ending the TB epidemic is one of the targets of the Sustainable Development Goals (SDGs) that requires intensive action by all countries, especially those with a high TB burden. The World Health Organization (WHO) End TB Strategy encompasses a package of interventions organized around the three pillars of integrated patient-centered care and prevention, bold policies and supportive systems and intensified research and innovation that should be adapted at country level. The End TB strategy requires the implementation of a combination of biomedical, public health and socioeconomic activities to accelerate the decline in global TB incidence and mortality rates while addressing all of the determinants of the TB epidemic with high-level commitment and a multisectoral approach.

The Global Ministerial Conference in Moscow in November 2017 created a new wave of hope for tackling several of the major hurdles hampering progress in the response to TB. The Moscow Declaration to End TB set out the commitments by Member States, and calls for specific actions by WHO and by partners, including civil society, at global and country level. These actions include ensuring sufficient and sustainable financing, pursuing science, research and innovation while recognizing that acceleration of progress toward the goal of ending TB requires action across the health sector and beyond. The Moscow Declaration also called for the development of a multisectoral accountability framework for TB that can be used to galvanize and sustain political commitment and action on TB at both global and national levels.

The global TB response is on the brink of a new era and the Moscow Declaration has helped to pave the way for the UN General Assembly High-Level Meeting on TB to be held in New York in September 2018. The UNGA High Level Meeting represents a unique opportunity to raise the profile of TB and secure the political commitment at the level of Heads of State to catalyze change towards reinvigorated and transformative TB efforts.

The Compendium of WHO TB guidelines and associated standards has been updated as a necessary guide to facilitate access to quality-assured diagnosis, treatment and care for all persons affected by TB.

Dr Tereza Kasaeva Global TB Programme

Acknowledgements

This compendium of WHO guidelines and associated standards was produced by Christopher Gilpin and Alexei Korobitsyn under the co-ordination of Karin Weyer. Overall guidance was provided by Mario Raviglione.

Contributions for the development of the document were received from Annabel Baddeley, Annemieke Brands, Monica Dias, Dennis Falzon, Haileyesus Getahun, Philippe Glaziou, Malgosia Grzemska, Yohhei Hamada, Ernesto Jaramillo, Knut Lönnroth, Fuad Mirzayev, Linh Nguyen, Kefas Samson, Lana Syed, Hazim Timimi, Mukund Uplekar, Wayne van Gemert, Diana Weil, Karin Weyer, and Matteo Zignol all from WHO's Global TB Programme.

The development and publication of this document has been made possible with the support of the United States Agency for International Development (USAID). Funding through the USAID-WHO Consolidated Grant No. GHA-G-00-09-00003/US 2015-826 is gratefully acknowledged.

Abbreviations

aDSM active TB drug safety monitoring and management

ART antiretroviral therapy

BCG bacille Calmette-Guérin

CPT co-trimoxazole preventive therapy

CXR chest X-ray

DOT directly observed treatment

DST drug-susceptibility testing

EPTB extrapulmonary tuberculosis

FDC fixed-dose combination

IGRA interferon gamma release assay

LF-LAM lateral flow urine lipoarabinomannan assay

LPA line probe assay

LTBI latent tuberculosis infection

MDGs Millennium Development Goals

MDR-TB multidrug-resistant tuberculosis

NGO nongovernmental organization

NTP National tuberculosis programme

RR-TB rifampicin-resistant tuberculosis

预览已结束,完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5_26178



